Figure 3
From: HSV1 microRNAs in glioblastoma development: an in silico study
Characterizing hsv1-miR-H6-3p targets. (A) EPB41L1 expression, (B) SH3PXD2A expression, (C) SH3TC2 expression, (D) SASH1 expression, (E) the prognostic values of EPB41L1 and SH3PXD2A in GBM patients. (F) Drug sensitivity analysis of EPB41L1 and SH3PXD2A based on GDSC. (G) Drug sensitivity analysis of EPB41L1 and SH3PXD2A based on CTRP. (H,I) EPB41L1 and SH3PXD2A expression in temozolomide-resistant GBM cell lines and normal astrocyte cells. (J) Immune cell infiltration and EPB41L1 and SH3PXD2A in GBM tissues.
